GARY WILLIAM SMALL

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc What we need to know about age related memory loss
    Gary W Small
    UCLA Neuropsychiatric Institute, Suite 88 201, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    BMJ 324:1502-5. 2002
  2. doi Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease
    Gary Small
    UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA
    Alzheimers Dement 7:177-84. 2011
  3. pmc Prediction of cognitive decline by positron emission tomography of brain amyloid and tau
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA
    Arch Neurol 69:215-22. 2012
  4. ncbi The role of neuroimaging in the diagnosis of vascular dementia
    G W Small
    Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, Los Angeles, CA 90024, USA
    Acta Neurol Scand Suppl 178:10-4. 2002
  5. ncbi In vivo brain imaging of tangle burden in humans
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, Los Angeles, CA, USA
    J Mol Neurosci 19:323-7. 2002
  6. ncbi Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease
    Gary Small
    Department of Psychiatry and Biobehavioral Sciences and Neuropsychiatric Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90024, USA
    CNS Drugs 17:905-14. 2003
  7. ncbi Seeing is believing: neuroimaging adds to our understanding of cerebral pathology
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, Alzheimer s Disease Center, University of California, Los Angeles, California 90024, USA
    Curr Opin Psychiatry 19:564-9. 2006
  8. ncbi Neuroimaging as a diagnostic tool in dementia with Lewy bodies
    Gary W Small
    Center on Aging, Neuropsychiatric Institute, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90024, USA
    Dement Geriatr Cogn Disord 17:25-31. 2004
  9. ncbi Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years
    G W Small
    UCLA Neuropsychiatric Institute, Los Angeles, CA 90024 1759, USA
    Int J Clin Pract 59:473-7. 2005
  10. ncbi Effects of a 14-day healthy longevity lifestyle program on cognition and brain function
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA
    Am J Geriatr Psychiatry 14:538-45. 2006

Collaborators

Detail Information

Publications73

  1. pmc What we need to know about age related memory loss
    Gary W Small
    UCLA Neuropsychiatric Institute, Suite 88 201, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    BMJ 324:1502-5. 2002
  2. doi Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease
    Gary Small
    UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA, USA
    Alzheimers Dement 7:177-84. 2011
    ..g., oral vs. transdermal), and treatment durations. Regardless of management approach, individuals with AD, their families, and caregivers have a right to a timely diagnosis and access to best available treatment...
  3. pmc Prediction of cognitive decline by positron emission tomography of brain amyloid and tau
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA
    Arch Neurol 69:215-22. 2012
    ..To determine whether 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) brain regional values in individuals without dementia predict and correlate with future cognitive change...
  4. ncbi The role of neuroimaging in the diagnosis of vascular dementia
    G W Small
    Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, Los Angeles, CA 90024, USA
    Acta Neurol Scand Suppl 178:10-4. 2002
    ..Neuroimaging also provides information about location and size of vascular lesions that can lead to a better understanding of symptoms and may help guide therapy...
  5. ncbi In vivo brain imaging of tangle burden in humans
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, Los Angeles, CA, USA
    J Mol Neurosci 19:323-7. 2002
    ....
  6. ncbi Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease
    Gary Small
    Department of Psychiatry and Biobehavioral Sciences and Neuropsychiatric Institute, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, California 90024, USA
    CNS Drugs 17:905-14. 2003
    ....
  7. ncbi Seeing is believing: neuroimaging adds to our understanding of cerebral pathology
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, Alzheimer s Disease Center, University of California, Los Angeles, California 90024, USA
    Curr Opin Psychiatry 19:564-9. 2006
    ..The purpose of this review is to provide background behind these developments and update readers on new findings...
  8. ncbi Neuroimaging as a diagnostic tool in dementia with Lewy bodies
    Gary W Small
    Center on Aging, Neuropsychiatric Institute, David Geffen School of Medicine at UCLA, Los Angeles, Calif 90024, USA
    Dement Geriatr Cogn Disord 17:25-31. 2004
    ....
  9. ncbi Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years
    G W Small
    UCLA Neuropsychiatric Institute, Los Angeles, CA 90024 1759, USA
    Int J Clin Pract 59:473-7. 2005
    ..3 (+/-4.9). Projected mean scores in model-based untreated patients declined below 10 points on the MMSE at about 3 years, while the mean MMSE score of patients who remained on rivastigmine stayed above 10 points for 5 years...
  10. ncbi Effects of a 14-day healthy longevity lifestyle program on cognition and brain function
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA
    Am J Geriatr Psychiatry 14:538-45. 2006
    ..The objective of this study was to determine the effects of a 14-day healthy longevity lifestyle program on cognition and cerebral metabolism in people with mild age-related memory complaints...
  11. ncbi Diagnostic issues in dementia: neuroimaging as a surrogate marker of disease
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, Alzheimer s Disease Center, and Center on Aging, University of California, Los Angeles, Los Angeles, CA, USA
    J Geriatr Psychiatry Neurol 19:180-5. 2006
    ..Combining imaging with genetic risk data will likely improve diagnostic accuracy. These new findings warrant reconsideration of current guidelines on the use of neuroimaging in diagnosis and research in dementia...
  12. ncbi PET of brain amyloid and tau in mild cognitive impairment
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and the Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at the University of California, Los Angeles, USA
    N Engl J Med 355:2652-63. 2006
    ..Noninvasive methods to detect these abnormal proteins are potentially useful in developing surrogate markers for drug discovery and diagnostics...
  13. ncbi A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch
    Gary Small
    UCLA Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024 1759, USA
    Curr Med Res Opin 23:2705-13. 2007
    ..Compliance in Alzheimer's disease (AD), a chronic neurodegenerative disease typically afflicting older adults, is especially challenging...
  14. pmc Current and future uses of neuroimaging for cognitively impaired patients
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA
    Lancet Neurol 7:161-72. 2008
    ....
  15. pmc Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at the University of California, Los Angeles, CA 90024, USA
    Am J Geriatr Psychiatry 16:999-1009. 2008
    ....
  16. pmc Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia
    Gary W Small
    Semel Institute, 760 Westwood Plaza, Ste 88 201, Los Angeles, CA 90024, USA
    Arch Gen Psychiatry 66:81-7. 2009
    ..Here we investigated whether known risk factors for Alzheimer disease and dementia are associated with FDDNP-PET binding...
  17. doi Your brain on Google: patterns of cerebral activation during internet searching
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, Los Angeles, CA, USA
    Am J Geriatr Psychiatry 17:116-26. 2009
    ....
  18. ncbi Vascular dementia: galantamine (Reminyl) as an emerging therapeutic option
    G W Small
    Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, Los Angeles, CA 90024, USA
    Acta Neurol Scand Suppl 178:4-5. 2002
  19. ncbi The impact of symptom severity on the cost of Alzheimer's disease
    Gary W Small
    Center on Aging, University of California Los Angeles, 90024, USA
    J Am Geriatr Soc 50:321-7. 2002
    ..ITo examine the economic impact of Alzheimer's disease (AD) as the disease progresses on patients' medical costs and caregivers' productivity...
  20. ncbi Memory self-appraisal and depressive symptoms in people at genetic risk for Alzheimer's disease
    G W Small
    Department of Psychiatry and Biobehavioral Sciences, The Neuropsychiatric Institute, University of California at Los Angeles, 90024, USA
    Int J Geriatr Psychiatry 16:1071-7. 2001
    ..No previous study has focused on subjective memory complaints and depressive symptoms in the same subject population at genetic risk for Alzheimer's disease...
  21. ncbi Investigations into geriatric psychiatry challenges: AAGP Senior Investigator Award 2000
    G W Small
    Department of Psychiatry and Biobehavioral Sciences, The Neuropsychiatric Institute, the Alzheimer s Disease Center, and the Center on Aging, University of California at Los Angeles, USA
    Am J Geriatr Psychiatry 8:276-83. 2000
    ..The eventual goal is to translate the clinical research discoveries into modern clinical practice...
  22. pmc Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease
    G W Small
    Center on Aging and Department of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    Proc Natl Acad Sci U S A 97:6037-42. 2000
    ..These results indicate that the combination of cerebral metabolic rates and genetic risk factors provides a means for preclinical AD detection that will assist in response monitoring during experimental treatments...
  23. ncbi Memory self-appraisal in middle-aged and older adults with the apolipoprotein E-4 allele
    G W Small
    Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles 90024 1759, USA
    Am J Psychiatry 156:1035-8. 1999
    ....
  24. ncbi Brain-imaging surrogate markers for detection and prevention of age-related memory loss
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and the Center on Aging, University of California, Los Angeles School of Medicine, USA
    J Mol Neurosci 19:17-21. 2002
    ....
  25. pmc FDDNP binding using MR derived cortical surface maps
    H D Protas
    Department of Biomathematics, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095, USA
    Neuroimage 49:240-8. 2010
    ....
  26. ncbi Estrogen use and brain metabolic change in older adults. A preliminary report
    N L Rasgon
    Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles, The Neuropsychiatric Institute, Los Angeles, CA 90095, USA
    Psychiatry Res 107:11-8. 2001
    ..These findings suggest that estrogen use may protect against regional cerebral metabolic decline in postmenopausal women...
  27. ncbi Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome
    D H Silverman
    Ahmanson Biological Imaging Center, CHS AR 144, Department of Molecular and Medical Pharmacology, University of California, Los Angeles School of Medicine, Los Angeles, CA 90095 6942, USA
    JAMA 286:2120-7. 2001
    ..Deficits in cerebral glucose utilization have been identified in patients with cognitive dysfunction attributed to various disease processes, but their prognostic and diagnostic value remains to be defined...
  28. ncbi In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile
    E D Agdeppa
    Division of Nuclear Medicine, Department of Molecular and Medical Pharmacology, Laboratory of Structural Biology and Molecular Medicine, The David Geffen School of Medicine at UCLA, Box 956948, Los Angeles, CA 90095, USA
    Neuroscience 117:723-30. 2003
    ....
  29. pmc Reduced cortical thickness in hippocampal subregions among cognitively normal apolipoprotein E e4 carriers
    A C Burggren
    David Geffen School of Medicine at UCLA, Center for Cognitive Neurosciences, Semel Institute, 760 Westwood Plaza B8 169, Los Angeles, CA 90095, USA
    Neuroimage 41:1177-83. 2008
    ....
  30. ncbi Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease
    A L Boxer
    Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA 94143 1207, USA
    Neurology 69:283-90. 2007
    ..To compare the in vivo uptake of two amyloid-binding PET agents, PIB and FDDNP, in human subjects with a prion protein (PrP) gene (PRNP) mutation that produces a clinical syndrome similar to Alzheimer disease (AD)...
  31. ncbi Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease
    E D Agdeppa
    Division of Nuclear Medicine, Department of Molecular and Medical Pharmacology, Laboratory of Structural Biology and Molecular Medicine, University of California Los Angeles School of Medicine, Los Angeles, California 90095, USA
    J Neurosci 21:RC189. 2001
    ....
  32. pmc Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome
    Linda D Nelson
    Department of Psychiatry and Biobehavioral Sciences, and Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles 90024, USA
    Arch Neurol 68:768-74. 2011
    ..For reference, [(18)F]FDDNP binding values and patterns were compared with those from patients with Alzheimer disease and cognitively intact control participants...
  33. ncbi Estrogen replacement therapy and antidepressant response to sertraline in older depressed women
    L S Schneider
    Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California, 1975 Zonal Ave, Los Angeles, CA 90033, USA
    Am J Geriatr Psychiatry 9:393-9. 2001
    ..The results provide preliminary evidence that ERT use (without progesterone) in older depressed women may augment the antidepressant response to sertraline in terms of quality of life and general improvement...
  34. ncbi Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits
    Daniel H S Silverman
    Department of Molecular and Medical Pharmacology and Ahmanson Biological Imaging Center, UCLA School of Medicine, University of California, Los Angeles 90095 6942, USA
    J Nucl Med 43:253-66. 2002
    ..The precise diagnostic role of PET and its economic impact in this context, however, have not been systematically examined previously...
  35. ncbi Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization
    Kooresh Shoghi-Jadid
    Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1766, USA
    Nucl Med Biol 32:337-51. 2005
    ....
  36. ncbi Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis
    Martin R Farlow
    Indiana University School of Medicine, Indianapolis, IN 46202 5111, USA
    Dement Geriatr Cogn Disord 20:192-7. 2005
    ..In a recent retrospective analysis, treatment effects of rivastigmine were more pronounced in AD patients with rapid cognitive decline than in those with slow cognitive decline. This warranted further investigation...
  37. pmc Serotonin 1A receptors in the living brain of Alzheimer's disease patients
    Vladimir Kepe
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 103:702-7. 2006
    ....
  38. ncbi Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET
    Daniel H S Silverman
    Department of Molecular and Medical Pharmacology, University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA
    Mol Genet Metab 80:350-5. 2003
    ..4). These data indicate that evaluation of brain metabolism by PET in appropriately selected patients may improve the accuracy of clinical prognostic assessment...
  39. ncbi Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease
    Kooresh Shoghi-Jadid
    Division of Nuclear Medicine, UCLA School of Medicine, Los Angeles, CA, USA
    Am J Geriatr Psychiatry 10:24-35. 2002
    ..0007). This noninvasive technique for monitoring AP and NFT development is expected to facilitate diagnostic assessment of patients with AD and assist in response-monitoring during experimental treatments...
  40. ncbi Spectral simulation methodology for calibration transfer of near-infrared spectra
    Yusuf Sulub
    Department of Chemistry and Optical Science and Technology Center, University of Iowa, Iowa City, Iowa 52242, USA
    Appl Spectrosc 61:406-13. 2007
    ..For instruments A and B, respectively, augmentation with measured spectra of nine samples lowers the SEP values to 0.64 and 0.85 mM...
  41. ncbi Visualizing pathology deposits in the living brain of patients with Alzheimer's disease
    Vladimir Kepe
    Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095, USA
    Methods Enzymol 412:144-60. 2006
    ..In contrast, control subjects have uniformly low levels of [F-18]FDDNP binding in all areas, which is comparable to that of cerebellum...
  42. doi Positron emission tomography scans obtained for the evaluation of cognitive dysfunction
    Daniel H S Silverman
    David Geffen School of Medicine, University of California, Los Angeles, CA, USA
    Semin Nucl Med 38:251-61. 2008
    ....
  43. ncbi Blank augmentation protocol for improving the robustness of multivariate calibrations
    Kirsten E Kramer
    Optical Science and Technology Center and Department of Chemistry, University of Iowa, Iowa City, IA 52242, USA
    Appl Spectrosc 61:497-506. 2007
    ..79 mM when the augmented PLS model is applied to data collected 176 days after the collection of the calibration spectra. Without updating, the original PLS model produces a seriously degraded SEP of 13.4 mM...
  44. ncbi 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease
    Eric D Agdeppa
    Department of Molecular and Medical Pharmacology, Laboratory of Structural Biology and Molecular Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 5:404-17. 2003
    ..Therefore it is anticipated that a new vision for prevention, early diagnosis and treatment of Alzheimer's disease would be rapidly developing...
  45. ncbi Object naming and semantic fluency among individuals with genetic risk for Alzheimer's disease
    Karen J Miller
    Department of Psychiatry and Biobehavioral Sciences, The Neuropsychiatric Institute, the Alzheimer s Disease Center, and the Center on Aging, University of California at Los Angeles, Los Angeles 90024 1759, USA
    Int J Geriatr Psychiatry 20:128-36. 2005
    ..This study longitudinally examined the object naming and semantic fluency of individuals who are at risk for developing Alzheimer's disease (AD) by virtue of having APOE-4 or a family history of AD...
  46. ncbi Estrogen use and brain metabolic change in postmenopausal women
    Natalie L Rasgon
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    Neurobiol Aging 26:229-35. 2005
    ..We used positron emission tomography to evaluate cerebral glucose metabolic change in postmenopausal women in a naturalistic observational study...
  47. ncbi An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia
    Timo Erkinjuntti
    Department of Clinical Neurosciences, Helsinki University Central Hospital, Helsinki, Finland
    Clin Ther 25:1765-82. 2003
    ....
  48. ncbi MMSE items predict cognitive decline in persons with genetic risk for Alzheimer's disease
    Linda M Ercoli
    Department of Psychiatry and Biobehavioral Sciences, and Neuropsychiatric Institute, University of California at Los Angeles, 90024, USA
    J Geriatr Psychiatry Neurol 16:67-73. 2003
    ..Performance on a subset of MMSE items, combined with APOE-4 genotype, may aid in identifying high-risk persons for research or follow-up...
  49. ncbi Multivariate calibration standardization across instruments for the determination of glucose by Fourier transform near-infrared spectrometry
    Lin Zhang
    Center for Intelligent Chemical Instrumentation, Department of Chemistry and Biochemistry, Clippinger Laboratories, Ohio University, Athens, Ohio 45701, USA
    Anal Chem 75:5905-15. 2003
    ..Diagnostic procedures are presented for use with the GMR algorithm that forecasts the successful calibration transfer with spectrometer C and the unsatisfactory results with spectrometer B...
  50. ncbi Prompt identification of Alzheimer's disease with brain PET imaging of a woman with multiple previous diagnoses of other neuropsychiatric conditions
    Daniel H S Silverman
    Department of Molecular and Medical Pharmacology, School of Medicine, University of California, Los Angeles 90095 6942, USA
    Am J Psychiatry 159:1482-8. 2002
  51. ncbi Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
    Michael W Jann
    Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, Atlanta, Georgia 30341, USA
    Clin Pharmacokinet 41:719-39. 2002
    ..The increased information available to clinicians can optimise the use of these agents in the management of patients with Alzheimer's disease...
  52. ncbi Hippocampal atrophy in persons with age-associated memory impairment: volumetry within a common space
    Michael S Mega
    Department of Neurology and Laboratory of Neuro Imaging, UCLA School of Medicine, Los Angeles, California 90095 1769, USA
    Psychosom Med 64:487-92. 2002
    ..The objective of this study is to demonstrate the assessment of hippocampal atrophy within a standard brain atlas for persons with age-associated memory impairment (AAMI) compared with cognitively intact elderly...
  53. pmc Age at onset in two common neurodegenerative diseases is genetically controlled
    Yi Ju Li
    Department of Medicine, Center for Human Genetics, Duke University Medical Center, Durham, NC 27710, USA
    Am J Hum Genet 70:985-93. 2002
    ..62. These data suggest that a common gene affects AAO in these two common complex neurodegenerative diseases...
  54. ncbi Academic highlights: emerging therapeutic strategies in Alzheimer's disease
    George T Grossberg
    Departments of Psychiatry and Internal Medicine, St Louis University Health Center and Wohl Clinic, St Louis, MO, USA
    J Clin Psychiatry 65:255-66; quiz 283-4. 2004
  55. ncbi Calibration standardization algorithm for partial least-squares regression: application to the determination of physiological levels of glucose by near-infrared spectroscopy
    Lin Zhang
    Center for Intelligent Chemical Instrumentation, Department of Chemistry and Biochemistry, Ohio University, Athens 45701, USA
    Anal Chem 74:4097-108. 2002
    ..A similar improvement in the prediction performance of the 2000 test set is obtained after standardization with the 1996 database (SEP = 0.70 mM)...
  56. ncbi Use of neuroimaging to detect early brain changes in people at genetic risk for Alzheimer's disease
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and the Center on Aging, University of California, Los Angeles School of Medicine, Los Angeles, CA, USA
    Adv Drug Deliv Rev 54:1561-6. 2002
    ....
  57. ncbi Analysis of European mitochondrial haplogroups with Alzheimer disease risk
    Joelle M van der Walt
    Department of Medicine, Center for Human Genetics, Duke University Medical Center, Durham, NC 27710, USA
    Neurosci Lett 365:28-32. 2004
    ..We suggest that variations within haplogroup U may be involved in AD expression in combination with environmental exposures or nuclear proteins other than APOE...
  58. ncbi Mood symptoms and cognitive performance in women estrogen users and nonusers and men
    Karen J Miller
    Department of Psychiatry and Biobehavioral Sciences, The Neuropsychiatric Institute, University of California, Los Angeles, CA 90024, USA
    J Am Geriatr Soc 50:1826-30. 2002
    ..In this study, we explore sex differences for a range of mood symptoms and for neuropsychological performance in men and postmenopausal women and assess the potential influence of estrogen on these measures...
  59. ncbi What does imaging add to the management of Alzheimer's disease?
    Gary W Small
    Neuropsychiatric Institute, University of California Los Angeles, 760 Westwood Plaza, Los Angeles, CA 90024, USA
    CNS Spectr 9:20-3. 2004
    ..If neurons can be protected from neurodegenerative damage in early stages, this may preserve patient cognition, function, and quality of life, and may confer considerable societal healthcare benefits...
  60. ncbi Specificity of brain activation patterns in people at genetic risk for Alzheimer disease
    Alison C Burggren
    Department of Psychiatry and Biobehavioral Sciences, Brain Mapping Division, UCLA School of Medicine, Los Angeles, CA 90095 7085, USA
    Am J Geriatr Psychiatry 10:44-51. 2002
    ....
  61. ncbi The Q7R Saitohin gene polymorphism is not associated with Alzheimer disease
    Sofia A Oliveira
    Department of Medicine and Center for Human Genetics, Institute for Genome Sciences and Policy, Box 3445, Duke University Medical Center, Durham, NC 27710, USA
    Neurosci Lett 347:143-6. 2003
    ..We found no evidence of significant association of this polymorphism with risk of AD using family-based and case-control tests of association...
  62. ncbi Parkin mutations and susceptibility alleles in late-onset Parkinson's disease
    Sofia A Oliveira
    Department of Medicine and Center for Human Genetics, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27710, USA
    Ann Neurol 53:624-9. 2003
    ..These findings suggest that mutations in Parkin contribute to the common form of PD and that heterozygous mutations, especially those lying in exon 7, act as susceptibility alleles for late-onset form of Parkinson disease...
  63. ncbi Association study of Parkin gene polymorphisms with idiopathic Parkinson disease
    Sofia A Oliveira
    Department of Medicine and Center for Human Genetics, Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC
    Arch Neurol 60:975-80. 2003
    ..However, previous case-control studies have reported conflicting results regarding the role of more common Parkin polymorphisms as susceptibility alleles for idiopathic PD...
  64. pmc Ordered-subsets linkage analysis detects novel Alzheimer disease loci on chromosomes 2q34 and 15q22
    William K Scott
    Department of Medicine, Duke University Medical Center, and Center for Human Genetics, Institute for Genome Sciences and Policy, Duke University, Durham, NC 27710, USA
    Am J Hum Genet 73:1041-51. 2003
    ..These results indicate that linkage to chromosome 9p is strongest in late-onset AD and that regions on chromosome 2q34 and 15q22 are linked to early-onset AD and very-late-onset AD, respectively...
  65. ncbi Comparison of combination and first overtone spectral regions for near-infrared calibration models for glucose and other biomolecules in aqueous solutions
    Jun Chen
    Department of Chemistry and Optical Science and Technology Center, University of Iowa, Iowa City, Iowa 52242, USA
    Anal Chem 76:5405-13. 2004
    ..The superior selectivity of combination spectra is confirmed by comparing the length of the NAS vectors for each matrix component...
  66. ncbi Scattering and absorption effects in the determination of glucose in whole blood by near-infrared spectroscopy
    Airat K Amerov
    Department of Chemistry and Optical Science and Technology Center, University of Iowa, Iowa City, Iowa 52242, USA
    Anal Chem 77:4587-94. 2005
    ..This result provides evidence that absorption information is needed in order to obtain a glucose calibration model with acceptable performance...
  67. ncbi Noninvasive glucose sensing
    Mark A Arnold
    Department of Chemistry and Optical Science and Technology Center, University of Iowa, Iowa City, Iowa 52242, USA
    Anal Chem 77:5429-39. 2005
    ..A set of publication standards is recommended as a means to enhance progress toward a successful noninvasive monitor...
  68. ncbi Pure component selectivity analysis of multivariate calibration models from near-infrared spectra
    Mark A Arnold
    Department of Chemistry, University of Iowa, Iowa City, Iowa 52242, USA
    Anal Chem 76:2583-90. 2004
    ..The proposed procedure demonstrates conclusively that no component of the sucrose or maltose spectrum contributes to the selective measurement of glucose. Analogous conclusions are possible for the sucrose and maltose calibration models...
  69. ncbi Remote detection of heated ethanol plumes by airborne passive Fourier transform infrared spectrometry
    Toshiyasu Tarumi
    Center for Intelligent Chemical Instrumentation, Department of Chemistry and Biochemistry, Clippinger Laboratories, Ohio University, Athens, Ohio 45701 2979, USA
    Appl Spectrosc 57:1432-41. 2003
    ..Further improvements in classification performance are judged to require increased sophistication in the ground-based data collection in order to provide a better match to the infrared backgrounds observed from the air...
  70. ncbi Classification of Fourier transform infrared microscopic imaging data of human breast cells by cluster analysis and artificial neural networks
    Lin Zhang
    Ohio University, Center for Intelligent Chemical Instrumentation, Department of Chemistry and Biochemistry, Clippinger Laboratories, Athens, Ohio 45701, USA
    Appl Spectrosc 57:14-22. 2003
    ..The robustness of the final classifier is improved through the use of a rejection threshold procedure to prevent classification of outlying pixels...
  71. ncbi Remote detection of volatile organic compounds by passive multispectral infrared imaging measurements
    Mukire J Wabomba
    Optical Science and Technology Center and Department of Chemistry, University of Iowa, Iowa City, Iowa 52242, USA
    Appl Spectrosc 61:349-58. 2007
    ..Separation of temperature and emissivity by use of the alpha residual calculation is found to reduce false positive detections to a negligible level, and the MNF transform is shown to enhance detection sensitivity...
  72. ncbi Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease
    Yi Ju Li
    Department of Medicine, Center for Human Genetics, Institute for Genome Science and Policy, Duke University Medical Center, Box 3445, Durham, NC 27710, USA
    Hum Mol Genet 12:3259-67. 2003
    ..This is provocative given reports of the possible role of inflammation in these two neurodegenerative disorders...
  73. doi Simulated radiance profiles for automating the interpretation of airborne passive multi-spectral infrared images
    Yusuf Sulub
    Department of Chemistry and Optical Science and Technology Center, University of Iowa, Iowa City, Iowa 52242, USA
    Appl Spectrosc 62:1049-59. 2008
    ..Field data collected during controlled releases of ethanol, as well as during a methanol release from an industrial facility, are used to evaluate the methodology...

Research Grants40

  1. FUNCTIONAL MRI FOR EARLY DIAGNOSIS OF ALZHEIMER DISEASE
    Gary Small; Fiscal Year: 2002
    ....
  2. FUNCTIONAL BRAIN IMAGING & MENTAL DISORDERS IN AGING
    Gary Small; Fiscal Year: 2002
    ..We hypothesize that a higher cerebral GABA concentration will be significantly related to a decrease in symptom response to divalproex sodium. ..
  3. MENTAL DISORDERS OF AGING--ANTIINFLAMMATION IN AD
    Gary Small; Fiscal Year: 2003
    ....
  4. Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down's Syndrome and Dementia
    Gary Small; Fiscal Year: 2009
    ..Given the many people suffering from these neurodegenerative diseases, the potential impact of this study will be considerable, possibly improving the quality of life for millions of patients and their families. ..
  5. FUNCTIONAL MRI FOR EARLY DIAGNOSIS OF ALZHEIMER'S
    Gary Small; Fiscal Year: 2004
    ....
  6. FUNCTIONAL MRI FOR EARLY DIAGNOSIS OF ALZHEIMER DISEASE
    Gary Small; Fiscal Year: 1999
    ....
  7. Glucose Metabolic, Amyloid, and Tau Brain Imaging in Down's Syndrome and Dementia
    GARY WILLIAM SMALL; Fiscal Year: 2010
    ..Given the many people suffering from these neurodegenerative diseases, the potential impact of this study will be considerable, possibly improving the quality of life for millions of patients and their families. ..